{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:16:59Z","timestamp":1783487819812,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06411-7","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:57:14Z","timestamp":1767880634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma"],"prefix":"10.1007","volume":"152","author":[{"given":"Sila","family":"Oksuz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oguzcan","family":"Kinikoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Ozkerim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Isik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heves","family":"Surmeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seval","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utku Donem","family":"Gundogdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba","family":"Basoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Odabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nedim","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"2","key":"6411_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4103\/ijc.IJC_1049_20","volume":"60","author":"T Basoglu","year":"2023","unstructured":"Basoglu T, Babacan NA, Ozturk FE, Arikan R, Demircan NC, Telli TA, Ercelep O, Dane F, Yumuk PF (2023) Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma. Indian J Cancer 60(2):179\u2013184 https:\/\/doi.org\/10.4103\/ijc.IJC_1049_20","journal-title":"Indian J Cancer"},{"key":"6411_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejca.2017.07.027","volume":"84","author":"F Bigot","year":"2017","unstructured":"Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S et al (2017) Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy immune score (GRIm-Score). Eur J Cancer 84:212\u2013218. https:\/\/doi.org\/10.1016\/j.ejca.2017.07.027","journal-title":"Eur J Cancer"},{"issue":"1","key":"6411_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Carac\u00f2 C, Ascierto PA (2018) Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer 6(1):74. https:\/\/doi.org\/10.1186\/s40425-018-0383-1PMID: 30012216; PMCID: PMC6048712","journal-title":"J Immunother Cancer"},{"issue":"31","key":"6411_CR8","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541\u20133543. https:\/\/doi.org\/10.1200\/JCO.2015.61.6870","journal-title":"J Clin Oncol"},{"issue":"6","key":"6411_CR11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.7150\/jca.37898","volume":"11","author":"JF Feng","year":"2020","unstructured":"Feng JF, Wang L, Yang X, Chen S (2020) Gustave Roussy immune score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma. J Cancer 11(6):1334\u20131340. https:\/\/doi.org\/10.7150\/jca.37898PMID: 32047540; PMCID: PMC6995395","journal-title":"J Cancer"},{"issue":"9","key":"6411_CR6","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamaoncol.2016.0775","volume":"2","author":"S George","year":"2016","unstructured":"George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI (2016) Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: A subgroup analysis of a randomized clinical trial. JAMA Oncol 2(9):1179\u20131186. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0775PMID: 27243803; PMCID: PMC5568541","journal-title":"JAMA Oncol"},{"issue":"2","key":"6411_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1148\/radiol.13130776","volume":"270","author":"MR Gray","year":"2014","unstructured":"Gray MR, Martin del Campo S, Zhang X, Zhang H, Souza FF, Carson WE 3rd, Smith AD (2014) Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab. Radiology 270(2):425\u2013434 Epub 2013 Oct 28. PMID: 24072776; PMCID: PMC3985552","journal-title":"Radiology"},{"key":"6411_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1475-2891-9-69","volume":"9","author":"D Gupta","year":"2010","unstructured":"Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69. https:\/\/doi.org\/10.1186\/1475-2891-9-69PMID: 21176210; PMCID: PMC3019132","journal-title":"Nutr J"},{"issue":"9","key":"6411_CR14","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M et al (2007) Programmed cell death one ligand one and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104(9):3360\u20133365. https:\/\/doi.org\/10.1073\/pnas.0611533104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"26","key":"6411_CR28","doi-asserted-by":"publisher","first-page":"e7325","DOI":"10.1097\/MD.0000000000007325","volume":"96","author":"C Hao","year":"2017","unstructured":"Hao C, Tian J, Liu H, Li F, Niu H, Zhu B (2017) Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Med (Baltim) 96(26):e7325. https:\/\/doi.org\/10.1097\/MD.0000000000007325PMID: 28658143; PMCID: PMC5500065","journal-title":"Med (Baltim)"},{"key":"6411_CR5","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the Immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887\u20133895","journal-title":"EMBO J"},{"key":"6411_CR4","first-page":"309","volume":"62","author":"JM Kirkwood","year":"2012","unstructured":"Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S (2012) Immunotherapy of cancer in 2012. CA Cancer J Clin 62:309\u2013335","journal-title":"CA Cancer J Clin"},{"key":"6411_CR15","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1245\/s10434-020-08821-y","volume":"28","author":"K Kudou","year":"2021","unstructured":"Kudou K, Nakashima Y, Haruta Y et al (2021) Comparison of inflammation-based prognostic scores associated with the prognostic impact of adenocarcinoma of the esophagogastric junction and upper gastric cancer. Ann Surg Oncol 28:2059\u20132067. https:\/\/doi.org\/10.1245\/s10434-020-08821-y","journal-title":"Ann Surg Oncol"},{"key":"6411_CR3","doi-asserted-by":"publisher","first-page":"681320","DOI":"10.3389\/fphar.2021.681320","volume":"12","author":"JB Lee","year":"2021","unstructured":"Lee JB, Ha SJ, Kim HR (2021) Clinical insights into novel immune checkpoint inhibitors. Front Pharmacol 12:681320","journal-title":"Front Pharmacol"},{"issue":"1","key":"6411_CR2","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.4110\/in.2022.22.e2","volume":"22","author":"JB Lee","year":"2022","unstructured":"Lee JB, Kim HR, Ha SJ (2022) Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw 22(1):e2. https:\/\/doi.org\/10.4110\/in.2022.22.e2","journal-title":"Immune Netw"},{"key":"6411_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.clnu.2018.07.015","volume":"38","author":"X Liu","year":"2019","unstructured":"Liu X, Wu Z, Lin E, Li W, Chen Y, Sun X, Zhou Z (2019) Systemic prognostic score and nomogram based on inflammatory, nutritional, and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy. Clin Nutr 38:1853\u20131860. https:\/\/doi.org\/10.1016\/j.clnu.2018.07.015","journal-title":"Clin Nutr"},{"issue":"1","key":"6411_CR29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s12967-023-04419-6","volume":"21","author":"D Mallardo","year":"2023","unstructured":"Mallardo D, Fordellone M, White A, Ottaviano M, Sparano F, Bailey M, Facchini AB, Ong S, Maiolino P, Carac\u00f2 C, Church S, Cavalcanti E, Warren S, Budillon A, Cesano A, Simeone E, Chiodini P, Ascierto PA (2023) CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy. J Transl Med 21(1):610. https:\/\/doi.org\/10.1186\/s12967-023-04419-6PMID: 37684649; PMCID: PMC10492378","journal-title":"J Transl Med"},{"issue":"3","key":"6411_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2217\/mmt-2016-0013","volume":"3","author":"M Mandal\u00e0","year":"2016","unstructured":"Mandal\u00e0 M, Merelli B, Massi D (2016) PD-L1 in melanoma: facts and myths. Melanoma Manag 3(3):187\u2013194","journal-title":"Melanoma Manag"},{"key":"6411_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.14740\/wjon1193","volume":"10","author":"S Minami","year":"2019","unstructured":"Minami S, Ihara S, Ikuta S, Komuta K (2019) Gustave Roussy immune score and Royal marsden hospital prognostic score are biomarkers of immune-Checkpoint inhibitor for non-small cell lung cancer. World J Oncol 10:90\u2013100. https:\/\/doi.org\/10.14740\/wjon1193","journal-title":"World J Oncol"},{"issue":"1","key":"6411_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/wjon1184","volume":"10","author":"S Minami","year":"2019","unstructured":"Minami S, Ihara S, Komuta K (2019) Gustave Roussy immune score is a prognostic factor for Chemotherapy-Naive pulmonary adenocarcinoma with Wild-Type epidermal growth factor receptor. World J Oncol 10(1):55\u201361. https:\/\/doi.org\/10.14740\/wjon1184Epub 2019 Feb 26. PMID: 30834052; PMCID: PMC6396777","journal-title":"World J Oncol"},{"key":"6411_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/wjon1184","volume":"10","author":"S Minami","year":"2019","unstructured":"Minami S, Ihara S, Komuta K (2019) Gustave Roussy immune score is a prognostic factor for chemotherapy-naive pulmonary adenocarcinoma with wild-type epidermal growth factor receptor. World J Oncol 10:55\u201361. https:\/\/doi.org\/10.14740\/wjon1184","journal-title":"World J Oncol"},{"key":"6411_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3892\/etm.2011.308","volume":"2","author":"H Miyata","year":"2011","unstructured":"Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y et al (2011) Prognostic value of an inflammation-based score in patients undergoing preoperative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med 2:879\u2013885. https:\/\/doi.org\/10.3892\/etm.2011.308","journal-title":"Exp Ther Med"},{"issue":"4","key":"6411_CR26","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther Apr 1 14(4):847\u2013856. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983","journal-title":"Mol Cancer Ther Apr 1"},{"issue":"4","key":"6411_CR7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4):847\u2013856. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983","journal-title":"Mol Cancer Ther"},{"key":"6411_CR9","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl Med 372:2006\u20132017. https:\/\/doi.org\/10.1056\/NEJMoa1414428","journal-title":"N Engl Med"},{"issue":"4","key":"6411_CR10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"issue":"5","key":"6411_CR1","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1093\/oncolo\/oyad016","volume":"28","author":"K Sadrolashrafi","year":"2023","unstructured":"Sadrolashrafi K, Samlowski W (2023) Retreatment of patients with metastatic cutaneous melanoma who relapse after elective checkpoint inhibitor discontinuation after a complete remission. Oncologist 28(5):e270\u2013e275. https:\/\/doi.org\/10.1093\/oncolo\/oyad016PMID: 36852837; PMCID: PMC10166161","journal-title":"Oncologist"},{"key":"6411_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3892\/br.2017.924","volume":"7","author":"Y Sato","year":"2017","unstructured":"Sato Y, Gonda K, Harada M, Tanisaka Y, Arai S, Mashimo Y et al (2017) The increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation, and chemotherapy outcomes in patients with locally advanced and metastatic esophageal squamous cell carcinoma. Biomed Rep 7:79\u201384. https:\/\/doi.org\/10.3892\/br.2017.924","journal-title":"Biomed Rep"},{"key":"6411_CR12","first-page":"491","volume":"32","author":"T Shimura","year":"2012","unstructured":"Shimura T, Kitagawa M, Yamada T, Ebi M, Mizoshita T, Tanida S et al (2012) C-reactive protein is a potential prognostic factor for metastatic gastric cancer. Anticancer Res 32:491\u2013496","journal-title":"Anticancer Res"},{"issue":"14","key":"6411_CR24","doi-asserted-by":"publisher","first-page":"e25318","DOI":"10.1097\/MD.0000000000025318","volume":"100","author":"J Xu","year":"2021","unstructured":"Xu J, Zhao J, Wang J, Sun C, Zhu X (2021) Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1\/PD-L1 therapy: A meta-analysis. Med (Baltim) 100(14):e25318 PMID: 33832106; PMCID: PMC8036123","journal-title":"Med (Baltim)"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06411-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06411-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06411-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:57:15Z","timestamp":1767880635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06411-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6411"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06411-7","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The need for informed consent was waived by the Kartal Dr. L\u00fctfi K\u0131rdar City Hospital\u2019s Ethics\/Institutional Review Board in compliance with national regulations, as outlined in the Regulation on Clinical Research (dated 13.04.2013, Official Gazette No. 28617, Page 17, Article 2.2).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki and approved by Kartal Dr. Lu\u0308tfi K\u0131rdar City Hospital\u2019s Ethics\/Institutional Review Board (date: March 26, 2025, no: 2025\/0l0.99\/14\/17).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"33"}}